- NEAR-IR GLUCOSE SENSORS
-
Glucose-sensing luminescent dyes, polymers, and sensors are provided. Additionally, systems including the sensors and methods of using these sensors and systems are provided.
- -
-
Paragraph 0550-0551
(2020/01/22)
-
- Use of novel haptens in the production of antibodies for the detection of tryptamines
-
Tryptamines are a group of hallucinogenic drugs whose detection in body fluids could be simplified by immunochemical assay kits. Antibodies for these assays are obtained by the immunization of laboratory animals with conjugates of a hapten similar to the target analyte and a suitable protein. Therefore we synthesized novel haptens derived from tryptamine-based drugs, with N,N-dimethyltryptamine (DMT), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-diisopropyltryptamine (DiPT) selected as the target analytes. Their structures were modified with a short linker ended with a carboxylic group. The haptens were conjugated with bovine serum albumin (BSA) and rabbits were immunized with the conjugates. The obtained polyclonal antibodies showed good reactivity and the LOD of the constructed ELISAs was in the range 0.006-0.254 ng mL-1. Thus, they are suitable for the development of immunochemical assay kits.
- Mary?ka, Michal,Fojtíková, Lucie,Jurok, Radek,Holubová, Barbora,Lap?ík, Old?ich,Kucha?, Martin
-
p. 16243 - 16250
(2018/05/22)
-
- NEAR-IR GLUCOSE SENSORS
-
Glucose-sensing luminescent dyes, polymers, and sensors are provided. Additionally, systems including the sensors and methods of using these sensors and systems are provided.
- -
-
Paragraph 0351; 0352
(2018/07/15)
-
- INDOLE-BASED COMPOUND, COLORANT COMPOSITION COMPRISING THE SAME AND RESIN COMPOSITION COMPRISING THE SAME
-
Disclosed in the present invention are a novel indole-based compound, a colorant composition comprising the same, and a resin composition comprising the same. Provided in an embodiment of the present invention is the compound represented by chemical formula 1. According to an embodiment of the present invention, the compound can be acted as a dye, and can be used as a material of a color filter. Specifically, the resin composition comprising the compound has a high color reproduction rate, high luminance, a high contrast ratio, etc.(AA) Comparative example 1(BB) Example 1(CC) Example 2(DD) Example 3(EE) Example 4(FF) Example 5(GG) Example 7(HH) Example 8(II) Example 9(JJ) Example 10COPYRIGHT KIPO 2016
- -
-
Paragraph 0257-0260
(2016/11/17)
-
- Structure-based design, synthesis and biological evaluation of N-pyrazole, N′-thiazole urea inhibitors of MAP kinase p38α
-
In this paper, we present the structure-based design, synthesis and biological activity of N-pyrazole, N′-thiazole-ureas as potent inhibitors of p38α mitogen-activated protein kinase (p38α MAPK). Guided by complex crystal structures, we employed the initially identified N-aryl, N′-thiazole urea scaffold and introduced key structural elements that allowed the formation of novel hydrogen bonding interactions within the allosteric site of p38α, resulting in potent type III inhibitors. [4-(3-tert-Butyl-5-{[(1,3-thiazol-2-ylamino)carbonyl]amino}-1H-pyrazol-1-yl) -phenyl]acetic acid 18c was found to be the most potent compound within this series and inhibited p38α activity with an IC50 of 135 ± 21 nM. Its closest analog, ethyl [4-(3-tert-butyl-5-{[(1,3-thiazol-2-ylamino) carbonyl]amino}-1H-pyrazol-1-yl)phenyl]acetate 18b, effectively inhibited p38α mediated phosphorylation of the mitogen activated protein kinase activated protein kinase 2 (MK2) in HeLa cells.
- Getlik, Matth?us,Grütter, Christian,Simard, Jeffrey R.,Nguyen, Hoang D.,Robubi, Armin,Aust, Beate,Van Otterlo, Willem A.L.,Rauh, Daniel
-
experimental part
p. 1 - 15
(2012/03/26)
-
- CYP2C9 structure-metabolism relationships: Optimizing the metabolic stability of COX-2 inhibitors
-
The cytochrome P450 (CYP) family is composed of a large group of monooxygenases that mediate the metabolism of xenobiotics and endogenous compounds. CYP2C9, one of the major isoforms of the CYP family, is responsible for the phase I metabolism of a variety of drugs. The aim of the present investigation is to use rational design together with MetaSite, a metabolism site prediction program, to synthesize compounds that retain their pharmacological effects but that are metabolically more stable in the presence of CYP2C9. The model compound for the study is the nonsteroidal anti-inflammatory drug celecoxib, a COX-2 selective inhibitor and known CYP2C9 substrate. Thirteen analogs of celecoxib were designed, synthesized, and evaluated with regard to their metabolic properties and pharmacologic effects. The docking solutions and the predictions from MetaSite gave useful information leading to the design of new compounds with improved metabolic properties.
- Ahlstr?m, Marie M.,Ridderstr?m, Marianne,Zamora, Ismael,Luthman, Kristina
-
p. 4444 - 4452
(2008/02/13)
-
- PI3 KINASES
-
The invention relates to the novel compounds of formula (1), which, due to their pharmaceutical effect as PI3 kinase modulators, are suitable for use in the therapy and treatment of inflammatory or allergic diseases. Examples of these diseases are inflammatory and allergic respiratory diseases, inflammatory diseases of the gastro-intestinal system and of the locomotor apparatus, inflammatory and allergic skin diseases, inflammatory ophthalmic diseases, diseases of the nasal mucosa, inflammatory or allergic autoimmune reactive conditions, or renal inflammations.
- -
-
Page/Page column 113
(2008/06/13)
-
- Therapeutic heterocyclic compounds
-
Compounds of formula (I) STR1 wherein R and R1 are hydrogen, C1-4 alkyl or are linked to form a ring, A is a cycloalkyl or alkyl-cycloalkyl group, n is an integer from 0 to 3, W is an optionally substituted 5-or 6-membered heterocycl
- -
-
-
